Drug Profile

ADRX 0706

Alternative Names: ADRX-0706

Latest Information Update: 09 Sep 2025

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Adcentrx Therapeutics
Class Antibodies; Antineoplastics; Drug conjugates; Immunoconjugates
Mechanism of Action Tubulin inhibitors

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes

Highest Development Phases

Phase I Solid tumours

Most Recent Events

30 May 2025 Efficacy, adverse events and pharmacokinetics data from a phase I trial in Solid tumours presented at the 61^stAnnual Meeting of the American Society of Clinical Oncology (ASCO-2025)
06 May 2025 ADRX 0706 receives Fast track status from the US FDA for Cervical cancer (Late-stage disease, Metastatic disease)
06 May 2024 NMPA approves IND application for ADRX 0706 in Solid tumours

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com